Herbalgy 25th Anniversary – Touch Cool- Peppermint Cooling to Soothe Various Pains Anytime, Anywhere
HONG KONG, Sept. 30, 2024 /PRNewswire/ -- Since its establishment in 1999, Herbalgy Pharmaceutical Ltd. has been dedicated to developing products that meet the diverse needs of Hong Kong people. In addition to the "Herbalgy" brand, they have launched two other brands, "Touch Cool" and "Tibet Red," over the past 25 years. The...
Mun Australia Introduces GloveOn COATS® Biodegradable Nitrile Gloves for Enhanced Skin Health and Sustainability
SYDNEY, Sept. 30, 2024 /PRNewswire/ -- Skin irritation is a common concern for workers who frequently wear gloves, and there's an increasing awareness of the need for sustainable product choices. This has led to a growing demand for gloves that not only protect the skin but also minimize environmental impact. In response, Mun Australia has launched its new GloveOn...
IASO Bio Presented Comparative Clinical Outcomes on the Optimal Lymphodepletion Prior to Infution of Equecabtagene Autoleucel（FucasoTM）in Patients with Relapsed Refractory Multiple Myeloma at 2024 IMS Annual Meeting
SHANGHAI and NANJING, China and SAN JOSE, Calif, Sept. 29, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, today announced a poster presentation of the comparative clinical outcomes of patients from FUMANBA-1 study with relapsed/refractory multiple myeloma (R/R MM) who received the fully human anti-BCMA...
SeromYx Systems and ACROBiosystems Announce Strategic Collaboration on Comprehensive Functional Profiling of Anti-CD20 Monoclonal Antibodies
NEWARK, Del., Sept. 29, 2024 /PRNewswire/ -- SeromYx Systems, a cutting-edge immunology technology company, and ACROBiosystems, an innovative provider for life science solutions and tools, are excited to announce the release of their joint study on the comprehensive functional profiling of approved anti-CD20 monoclonal antibodies (mAbs). The collaboration leverages SeromYx's advanced biophysical and cellular Fc-effector function platform and ACROBiosystems'...
Multiple Study Results of Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) at 2024 CSCO Congress
CHENGDU, China, Sept. 29, 2024 /PRNewswire/ -- From September 25th to 29th, the 27th China Clinical Oncology Congress and the 2024 CSCO Annual Meeting were held in Xiamen. Experts and scholars in the field of oncology from all over China gathered together to discuss the hotspots at the forefront of clinical practice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", 6990.HK)...
New Beginnings, New Journey | Sanyou Opening of New 10,000-sqm Facility, Ushering in a New Era of Innovation for Bio Drugs
SHANGHAI, Sept. 28, 2024 /PRNewswire/ -- Sanyou Bio recently celebrated a prestigious move into its new 10,000-square-meter R&D building at Shanghai headquarters. This is not just a change in physical location, but a qualitative leap in the company infrastructure. It marks a solid step forward for Sanyou Bio to accelerate the development of innovative biologics and advance its mission...
Frost & Sullivan Released Report: “2024 Blue Book on Chinese Biopharmaceuticals Going Global: Current Status and Trends”
SHANGHAI, Sept. 28, 2024 /PRNewswire/ -- Frost & Sullivan released the "2024 Blue Book on Chinese Biopharmaceuticals Going Global: Current Status and Trends" which focus on the progress of Chinese biopharmaceuticals going global and analyzes the driving forces behind their accelerated global expansion. The Blue Book also offers a multi-faceted exploration of the development trends and value orientation of Chinese...
111, Inc. Announces Receipt of Notification from Nasdaq
SHANGHAI, Sept. 28, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced it has received a notification letter dated September 26, 2024 (the "Notice") from the staff of the Listing Qualifications...
TraceLink Propels Organizations Toward DSCSA Compliance Ahead of the November 2024 Deadline
BOSTON, Sept. 27, 2024 /PRNewswire/ -- With the Drug Supply Chain Security Act (DSCSA) stabilization period ending on November 27, 2024, the TraceLink customer and trading partner community of healthcare and life sciences companies continues to demonstrate market leadership in demonstrating compliance readiness. TraceLink's 290,000-strong B2N Integrate-Once™network has been instrumental in supporting...
Ping An Healthcare and Technology Stock Soared 10% – Managed Care Takes Center Stage in Corporate Health Management
SHANGHAI, Sept. 27, 2024 /PRNewswire/ -- On September 26, 2024, Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health", or "the Company", Stock Code: 1833.HK), China's leading healthcare ecosystem platform, saw its share price surge by nearly 10% during the trading session, peaking at HK$12.08. The U.S. Federal Reserve's recent announcement of a 50...
